Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07677059 · ClinicalTrials.gov registry record · Phase 2
A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
A Phase 2 study, sponsored by Kymera Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 264
- Enrollment target
NCT07677059 is a Phase 2 study that is actively recruiting participants, run by Kymera Therapeutics. The registered enrollment target is 264 participants.
The verdict
NCT07677059, a Phase 2 study, is actively recruiting participants, sponsored by Kymera Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 264 participants
- Enrollment target
Study Summary
This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.
Interventions
- DRUG KT-621
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07677059
The ClinicalTrials.gov registry entry for NCT07677059 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kymera Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KT-621 is the first listed.
NCT07677059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07677059 about?
NCT07677059 is a clinical study titled "A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study". This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safe...
What is the current status of trial NCT07677059?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 264 participants. The study started on 2026-07. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07677059?
The interventions under investigation include: KT-621 (DRUG).
Who is sponsoring clinical trial NCT07677059?
This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.